Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer - Episode 12
Expert Insights: Investigational ADCs Safety Profiles
Panelists discuss how, despite the investigational status of agents like patritumab deruxtecan (HER3-DXd) and datopotamab deruxtecan (Dato-DXd), it’s crucial for community oncologists to be aware of the treatment-related adverse effects (TRAEs) associated with these therapies and to consider effective management strategies as reported in clinical trials.
Video content above is prompted by the following:
- While these agents are still investigational, and their safety profiles have not been officially established…
- Can you comment on any pertinent treatment-related adverse effects (TRAEs) associated with patritumab deruxtecan (HER3-DXd) reported in these clinical trials that the community oncologists should be aware of and your respective management strategies?
- Please comment on any pertinent TRAEs associated with datopotamab deruxtecan (Dato-DXd) reported in these clinical trials that the community oncologists should be aware of and your respective management strategies.
Related Content:
